MCID: RTN021
MIFTS: 45

Retinal Vascular Occlusion

Categories: Eye diseases, Cardiovascular diseases

Aliases & Classifications for Retinal Vascular Occlusion

MalaCards integrated aliases for Retinal Vascular Occlusion:

Name: Retinal Vascular Occlusion 12 52 14 69
Retinal Vascular Occlusion, Unspecified 12
Unspecified Retinal Vascular Occlusion 12
Retinal Vascular Occlusion Nos 12
Retinal Vasc. Occlusion 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1729
ICD10 33 H34 H34.9
ICD9CM 35 362.3 362.30
NCIt 47 C34980
UMLS 69 C0035326

Summaries for Retinal Vascular Occlusion

MalaCards based summary : Retinal Vascular Occlusion, also known as retinal vascular occlusion, unspecified, is related to central retinal artery occlusion and mcgillivray syndrome, and has symptoms including amaurosis fugax An important gene associated with Retinal Vascular Occlusion is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Retinal Vascular Occlusion

Diseases related to Retinal Vascular Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
id Related Disease Score Top Affiliating Genes
1 central retinal artery occlusion 29.4 APOH F2 FANCG MTHFR SERPINC1
2 mcgillivray syndrome 10.8 APOH F5
3 accessory deep peroneal nerve 10.7 APOH F5
4 multicentric osteolysis nephropathy 10.7 F5 MTHFR
5 central retinal vein occlusion 10.7
6 coronary sinus stenosis 10.7 F5 MTHFR
7 amelogenesis imperfecta hypomaturation type 10.6 F5 MTHFR
8 hereditary amyloidosis 10.6 SELP SERPINC1
9 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.6 F5 SELP
10 colorectal adenoma 10.6 PLG VEGFA
11 hypertonia 10.6 MTHFR VEGFA
12 iliac vein thrombophlebitis 10.6 PLG VEGFA
13 stoll alembik finck syndrome 10.6 F5 SERPINC1
14 retinitis 10.6
15 variably protease-sensitive prionopathy 10.6 F2 F5
16 landau-kleffner syndrome 10.6 APOH F2
17 perineurioma 10.6 PLG VEGFA
18 myxomatous pattern testicular yolk sac tumor 10.5 APOH F5
19 prostatitis 10.5 APOH F2
20 bile duct cystadenoma 10.5 F2 F5
21 anterior cerebral artery infarction 10.5 APOH PLG
22 hyperthyroidism 10.5 F2 PLG
23 american histoplasmosis 10.5 SELP SERPINC1
24 porphyria 10.5 F2 MTHFR
25 brain stem glioma 10.5 F2 PLG
26 facioscapulohumeral muscular dystrophy 1 10.5 F2 F5
27 central nervous system germ cell tumor 10.5 F2 PLG
28 arcus senilis 10.5 MTHFR PLG
29 mental retardation dysmorphism hypogonadism diabetes 10.5 F5 SERPINC1
30 factor v deficiency 10.4 F2 F5
31 fragile x syndrome type 2 10.4 F2 SERPINC1
32 purulent endophthalmitis 10.4 PLG VEGFA
33 segawa syndrome, recessive 10.4 F2 SELP
34 bladder squamous papilloma 10.4 FANCG PLG
35 pregnancy loss, recurrent 1 10.4 APOH F5 MTHFR
36 congenital ichthyosiform erythroderma 10.4 PGF VEGFA
37 coccidioidomycosis 10.4 F2 PLG
38 cavernous lymphangioma 10.4 APOH F5 MTHFR
39 acitretin/etretinate embryopathy 10.4 PGF VEGFA
40 coloboma of superior eyelid 10.4 PGF VEGFA
41 pilomyxoid astrocytoma 10.4 F2 SERPINC1
42 inferolateral myocardial infarct 10.4 F2 SERPINC1
43 angelucci's syndrome 10.4 F2 SERPINC1
44 angioedema, hereditary, type iii 10.4 APOH F5 SERPINC1
45 stickler sydrome, type i, nonsyndromic ocular 10.4 APOH F5 SERPINC1
46 lethal congenital contracture syndrome 10.4 F2 SERPINC1
47 streptococcal meningitis 10.4 APOH CCL2
48 hard palate cancer 10.3 F2 VEGFA
49 46,xy ovotesticular disorder of sex development 10.3 APOH F2 F5
50 essential thrombocythemia 10.3 F2 SERPINC1

Comorbidity relations with Retinal Vascular Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Retinal Vascular Occlusion:



Diseases related to Retinal Vascular Occlusion

Symptoms & Phenotypes for Retinal Vascular Occlusion

UMLS symptoms related to Retinal Vascular Occlusion:


amaurosis fugax

MGI Mouse Phenotypes related to Retinal Vascular Occlusion:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 APOH F2 F5 MTHFR PGF PLG
2 cardiovascular system MP:0005385 9.8 F2 F5 PGF PLG SELP SERPINC1
3 integument MP:0010771 9.5 F2 F5 MTHFR PGF PLG SELP
4 vision/eye MP:0005391 9.1 PGF PLG SELP SERPINC1 VEGFA MTHFR

Drugs & Therapeutics for Retinal Vascular Occlusion

Drugs for Retinal Vascular Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
4
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
7 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 4,Phase 3,Phase 2
11 Fibrinolytic Agents Phase 4,Phase 3,Phase 1
12 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
13 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
14 Antiemetics Phase 4,Phase 2,Phase 3
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
17 Autonomic Agents Phase 4,Phase 2,Phase 3
18 BB 1101 Phase 4,Phase 2,Phase 3
19 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
20 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
21 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
27
protease inhibitors Phase 4,Phase 2,Phase 3
28 Anticoagulants Phase 4,Phase 3
29 Glucuronyl glucosamine glycan sulfate Phase 4
30 Hypoglycemic Agents Phase 4
31 Anesthetics Phase 4,Phase 3
32 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
33 Antibodies Phase 4
34 Antibodies, Monoclonal Phase 4
35 Immunoglobulins Phase 4
36
Triamcinolone Approved, Vet_approved Phase 3,Phase 1 124-94-7 31307
37
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
38
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
40
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028
41
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
42
Salicylic acid Approved, Vet_approved Phase 3 69-72-7 338
43
Dalteparin Approved Phase 3 9005-49-6
44
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
46
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
47
Nicotinamide Approved, Nutraceutical Phase 2, Phase 3 98-92-0 936
48 Anticholesteremic Agents Phase 3
49 Atorvastatin Calcium Phase 3 134523-03-8
50 Calcium, Dietary Phase 3

Interventional clinical trials:

(show top 50) (show all 113)

id Name Status NCT ID Phase Drugs
1 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
2 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
3 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Unknown status NCT01896284 Phase 4 0.5mg aflibercept
4 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
5 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
6 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
7 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
8 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
9 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
10 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
11 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
12 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
13 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
14 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4 Ranibizumab
15 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4 Aflibercept
16 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4 Ranibizumab
17 Strategies for Management of Corneal Neovascularisation Not yet recruiting NCT02594423 Phase 4 Bevacizumab
18 Bevacizumab and Retinal Vascular Occlusions Unknown status NCT00347711 Phase 3 Intravitreal injection
19 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
20 Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Unknown status NCT01189526 Phase 3 Ranibizumab
21 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Unknown status NCT01635803 Phase 2, Phase 3 Bevacizumab;Ranibizumab
22 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
23 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3 Sham
24 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
25 Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage Completed NCT00106132 Phase 3 Triamcinolone Acetonide
26 Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
27 Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions Completed NCT00500045 Phase 2, Phase 3 nicotinic acid
28 To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions Completed NCT00493064 Phase 2, Phase 3 Nicotinic acid;Prednisolone acetate
29 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed NCT01599650 Phase 3 Ranibizumab
30 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
31 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
32 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
33 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
34 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
35 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
36 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
37 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3 triamcinolone and bevacizumab
38 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Completed NCT01449682 Phase 3 Ozurdex;Ozurdex
39 A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion Not yet recruiting NCT03197194 Phase 3 Alteplase;acetylsalicylic acid;Placebo Oral Tablet;placebo IV
40 Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion Terminated NCT00732927 Phase 3 parnaparin;aspirin
41 The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform Unknown status NCT00802698 Phase 1, Phase 2
42 Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT01123564 Phase 2 ranibizumab
43 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
44 Pain and Visual Outcome in Intravitreal Bevacizumab Injection Completed NCT02790775 Phase 2 Anti-VEGF in quadrant 1;Anti-VEGF in quadrant 2;Anti-VEGF in quadrant 3;Anti-VEGF in quadrant 4
45 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study Completed NCT01247220 Phase 2 Ranibizumab
46 Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF Completed NCT02118831 Phase 1, Phase 2 Aflibercept;Bevacizumab;Ranibizumab
47 Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT00088283 Phase 2 pegaptanib sodium
48 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions Completed NCT01003106 Phase 1, Phase 2 Ranibizumab 0.5mg (monthly);Ranibizumab 2.0mg (monthly);Pro re nata (prn) ranibizumab
49 Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00709423 Phase 2 Moxaverine;Moxaverin 150mg;NaCl
50 The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo Recruiting NCT03090087 Phase 2 Regadenoson

Search NIH Clinical Center for Retinal Vascular Occlusion

Genetic Tests for Retinal Vascular Occlusion

Anatomical Context for Retinal Vascular Occlusion

MalaCards organs/tissues related to Retinal Vascular Occlusion:

39
Eye, Endothelial, Bone

Publications for Retinal Vascular Occlusion

Articles related to Retinal Vascular Occlusion:

(show top 50) (show all 77)
id Title Authors Year
1
Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy. ( 28771491 )
2017
2
Retinal Vascular Occlusion Secondary to Retrobulbar Injection: Case Report and Literature Review. ( 28546695 )
2017
3
Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes. ( 27563233 )
2016
4
Venous thromboembolism does not share familial susceptibility with retinal vascular occlusion or glaucoma: a nationwide family study. ( 27283943 )
2016
5
Risk of Mortality and of Atherosclerotic Events Among Patients Who Underwent Hemodialysis and Subsequently Developed Retinal Vascular Occlusion: A Taiwanese Retrospective Cohort Study. ( 26720586 )
2016
6
ADULT WITH CHICKENPOX COMPLICATED BY SYSTEMIC VASCULITIS AND BILATERAL RETINAL VASCULITIS WITH RETINAL VASCULAR OCCLUSIONS. ( 27533640 )
2016
7
SEVERE BILATERAL RETINAL VASCULAR OCCLUSION AS FIRST PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME. ( 27548039 )
2016
8
Oral contraceptive pills: A risk factor for retinal vascular occlusion in in-vitro fertilization patients. ( 23869159 )
2013
9
Pipeline embolization device: a new source for embolic retinal vascular occlusion. ( 24051422 )
2013
10
Impact of cilostazol on the progression of carotid atherosclerosis in patients with retinal vascular occlusion. ( 24034133 )
2013
11
Central retinal vascular occlusion associated with acute retinal necrosis. ( 22491922 )
2012
12
Thrombophilia and retinal vascular occlusion. ( 22969282 )
2012
13
Retinal vascular occlusion after vitrectomy with retrobulbar anesthesia-observational case series and survey of literature. ( 21850439 )
2011
14
Retinal vascular occlusion during in vitro fertilization. ( 25390129 )
2010
15
Factor V Leiden mutation with retinal vascular occlusion. ( 21199226 )
2010
16
Retinal vascular occlusions occur more frequently in the more affected eye in exfoliation syndrome. ( 19557023 )
2010
17
Retinal vascular occlusion syndromes. ( 19584622 )
2009
18
Paroxysmal nocturnal hemoglobinuria may cause retinal vascular occlusions. ( 18437293 )
2009
19
Retinal vascular occlusions: an interdisciplinary challenge. ( 19626196 )
2008
20
Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. ( 17481600 )
2007
21
Role of hyperhomocystinemia in retinal vascular occlusive disease. ( 17164500 )
2007
22
Inappropriate investigation and management of a retinal vascular occlusion. ( 16082396 )
2006
23
Retinal vascular occlusion in patients infected with human immunodeficiency virus. ( 16141865 )
2005
24
[The characteristics of retinitis pigmentosa with retinal vascular occlusion]. ( 15938805 )
2005
25
Retinal vascular occlusion following traumatic hyphema and glaucoma, as a presenting sign of sickle cell trait. ( 16011069 )
2005
26
Retinal vascular occlusion following ocular contusion. ( 15931542 )
2005
27
Retinal vascular occlusion with overlying vitreous hemorrhage masquerading as a tumor. ( 15710833 )
2005
28
Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy. ( 16197292 )
2005
29
Hyperhomocysteinaemia: risk of retinal vascular occlusion. ( 16335656 )
2004
30
Central retinal vascular occlusion by orbital pseudotumor. ( 15187672 )
2004
31
Unilateral peripheral retinal vascular occlusion in a young Japanese woman with neurofibromatosis-1. ( 12972769 )
2003
32
Factor V Leiden mutation does not correlate with retinal vascular occlusion in white patients with BehAset's disease. ( 12881356 )
2003
33
Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. ( 14644226 )
2003
34
Thermolabile MTHFR genotype and retinal vascular occlusive disease. ( 11133719 )
2001
35
[Retinal vascular occlusion and primary antiphospholipid syndrome. Report of 2 cases]. ( 11912840 )
2001
36
[Thrombophilia factors as inducers of retinal vascular occlusion]. ( 11450475 )
2001
37
The electroretinogram in patients with retinal vascular occlusion. ( 12567597 )
2001
38
Retinal vascular occlusion and deficiencies in the protein C pathway. ( 10653431 )
2000
39
Retinal vascular occlusion and deficiencies in the protein C pathway. ( 10653432 )
2000
40
Systemic disorders associated with retinal vascular occlusion. ( 11141642 )
2000
41
Genetic thrombophilia in patients with retinal vascular occlusion. ( 11456253 )
1999
42
Retinal vascular occlusion and deficiencies in the protein C pathway. ( 10482096 )
1999
43
Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. ( 9683948 )
1998
44
Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance. ( 9372725 )
1997
45
Visual field loss caused by retinal vascular occlusion after vitrectomy surgery. ( 9152086 )
1997
46
Cocaine-associated retinal vascular occlusion: report of two cases. ( 8059789 )
1994
47
Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. ( 8002838 )
1994
48
Lipoprotein (a): a risk factor for retinal vascular occlusion. ( 1477637 )
1992
49
The investigation of patients with retinal vascular occlusion. ( 2209910 )
1990
50
Massive bilateral retinal vascular occlusion. ( 2475899 )
1989

Variations for Retinal Vascular Occlusion

Expression for Retinal Vascular Occlusion

Search GEO for disease gene expression data for Retinal Vascular Occlusion.

Pathways for Retinal Vascular Occlusion

GO Terms for Retinal Vascular Occlusion

Cellular components related to Retinal Vascular Occlusion according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 APOH CCL2 F2 F5 PGF PLG
2 blood microparticle GO:0072562 9.43 F2 PLG SERPINC1
3 platelet alpha granule lumen GO:0031093 9.33 F5 PLG VEGFA
4 extracellular space GO:0005615 9.28 APOH CCL2 F2 F5 PGF PLG

Biological processes related to Retinal Vascular Occlusion according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 F2 F5 PLG SERPINC1
2 regulation of cell shape GO:0008360 9.72 CCL2 F2 VEGFA
3 blood coagulation GO:0007596 9.71 F2 F5 PLG SERPINC1
4 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.67 CCL2 PGF VEGFA
5 response to hypoxia GO:0001666 9.67 CCL2 MTHFR PGF VEGFA
6 positive regulation of endothelial cell proliferation GO:0001938 9.65 CCL2 PGF VEGFA
7 positive regulation of collagen biosynthetic process GO:0032967 9.57 CCL2 F2
8 fibrinolysis GO:0042730 9.56 F2 PLG
9 blood coagulation, intrinsic pathway GO:0007597 9.54 APOH F2
10 induction of positive chemotaxis GO:0050930 9.52 PGF VEGFA
11 positive regulation of blood coagulation GO:0030194 9.51 APOH F2
12 regulation of blood coagulation GO:0030193 9.5 APOH F2 SERPINC1
13 positive regulation of mast cell chemotaxis GO:0060754 9.46 PGF VEGFA
14 positive regulation of leukocyte migration GO:0002687 9.43 CCL2 SELP VEGFA
15 negative regulation of fibrinolysis GO:0051918 9.33 APOH F2 PLG
16 hemostasis GO:0007599 9.26 F2 F5 PLG SERPINC1
17 platelet degranulation GO:0002576 9.02 APOH F5 PLG SELP VEGFA

Molecular functions related to Retinal Vascular Occlusion according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 F2 PGF VEGFA
2 lipopolysaccharide binding GO:0001530 9.26 F2 SELP
3 heparin binding GO:0008201 9.17 APOH CCL2 F2 PGF SELP SERPINC1
4 vascular endothelial growth factor receptor binding GO:0005172 8.96 PGF VEGFA

Sources for Retinal Vascular Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....